MicroRNA as a biomarker for prediction of HCC development after achieving an SVR
Project/Area Number |
16K09369
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Osaka City University |
Principal Investigator |
Enomoto Masaru 大阪市立大学, 大学院医学研究科, 准教授 (20423874)
|
Co-Investigator(Kenkyū-buntansha) |
村上 善基 大阪市立大学, 大学院医学研究科, 准教授 (00397556)
河田 則文 大阪市立大学, 大学院医学研究科, 教授 (30271191)
田守 昭博 大阪市立大学, 大学院医学研究科, 准教授 (30291595)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | C型肝炎 / マイクロRNA / SVR / 線維化 / バイオマーカー / 内科 / 肝炎 |
Outline of Final Research Achievements |
Direct-acting antivirals (DAAs) can result in a sustained virologic response (SVR) in >90% of patients with chronic hepatitis C virus (HCV) infection. This study aimed to evaluate histological improvement after obtaining an SVR to DAAs in patients with HCV. Among 691 patients with chronic hepatitis C who had an SVR to DAAs, 51 underwent liver biopsy 41±20 weeks after the end of therapy. In 20 patients, liver biopsies obtained a median of 1.2 years before the start of treatment were available. Among the 51 patients who underwent post-SVR biopsies, the grade of inflammation was A0 in 18, A1 in 24, A2 in 8, and A3 in 1; the stage of fibrosis was F0 in 3, F1 in 20, F2 in 15, F3 in 9, and F4 in 4. In the 20 paired biopsies, the inflammation grade regressed (p = 0.0043), but the fibrosis stage did not (p = 0.45). Even if ALT become normal after having an SVR, significant histological inflammation was found in some patients. The improvement in liver fibrosis was not evident in the short term
|
Academic Significance and Societal Importance of the Research Achievements |
我が国には500万人以上の慢性肝疾患患者が存在するが、その数は非アルコール性脂肪肝炎の増加に伴い増え続けている。また慢性肝疾患の終末像である肝硬変からは、例え肝炎ウイルスが制御されたとしても年率3~7%の割合で肝発がんが起こると考えられている。肝発がんは肝の壊死・炎症と線維化に密接に関係しており、肝線維化に関連するバイオマーカーの探索から肝発がんの機構を明らかにし、発がん高リスク患者を囲い込もうとする本研究の学術的意義は非常に高い。慢性肝疾患の制御は公衆衛生上も大変重要な国民的健康問題であり、臨床的にこれに利用可能なバイオマーカーを開発することが出来れば社会的に貢献できる可能性がある。
|
Report
(4 results)
Research Products
(27 results)
-
-
[Journal Article] Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.2018
Author(s)
Motoyama H, Tamori A, Kubo S, Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N.
-
Journal Title
PLoS One.
Volume: 13
Issue: 3
Pages: 0194163-0194163
DOI
NAID
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
[Journal Article] 4.Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with HCV genotype 1b2016
Author(s)
Tamori A, Yoshida K, Kurai O, Kioka K, Hai H, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N
-
Journal Title
Hepatol Res.
Volume: 46
Issue: 8
Pages: 1311-1320
DOI
Related Report
Peer Reviewed / Int'l Joint Research / Acknowledgement Compliant
-
-
-
[Journal Article] Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with HCV genotype 1b.2016
Author(s)
Tamori A, Yoshida K, Kurai O, Kioka K, Hai H, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N.
-
Journal Title
Hepatol Res
Volume: 印刷中
Issue: 13
Pages: 1311-1320
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
[Presentation] Establishing Efficient Systems through Electronic Medical Records to Promote Intra-Hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire Survey of 1,314 Healthcare2018
Author(s)
Masaru Enomoto, Syuuichi Sato, Atsushi Suetsugu, Tomomitsu Matono, Isao Hidaka, Minoru Sakamoto, Mika Horino, Kiyoaki Ito, Koji Ogawa, Jun Inoue, Masaaki Korenaga
Organizer
69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Related Report
Int'l Joint Research
-
[Presentation] “Normal” ALT by central laboratory criteria but >30 U/L for males and >19 U/L for females is predictive of residual inflammation in liver biopsies after sustained virologic response to direct-acting antivirals for chronic hepatitis C2018
Author(s)
Masaru Enomoto, Yoshihiro Ikura, Akihiro Tamori, Ritsuzo Kozuka, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Hiroyasu Morikawa, Yoshiki Murakami, Norifumi Kawada
Organizer
69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Related Report
Int'l Joint Research
-
-
-
-
-
[Presentation] Short-term histological evaluations after achieving a sustained virological response to direct-acting antiviral treatment for chronic hepatitis C2017
Author(s)
Masaru Enomoto, Akihiro Tamori, Ritsuzo Kozuka, Hiroyuki Motoyama, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Hiroyasu Morikawa, Yoshiki Murakami, Yoshihiro Ikura, Norifumi Kawada
Organizer
68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Related Report
Int'l Joint Research
-
-
[Presentation] Promotion of intra-hospital referral of hepatitis B and C virus carriers to hepatology specialists by electronic medical record-based alert system: a case study at a university hospital2016
Author(s)
M. Enomoto, S. Uchida-Kobayashi, H. Fujii, A. Iida-Ueno, H. Motoyama, R. Kozuka, A. Hagihara, E. Kawamura, H. Morikawa, Y. Murakami, A. Tamori, N. Kawada
Organizer
24th United European Gastroenterology Week (UEGW)
Place of Presentation
ウイーン(オーストリア)
Year and Date
2016-10-15
Related Report
Int'l Joint Research
-